MedTrace Logo

Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia

NCT00818610 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 601

Last updated 2013-04-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.

Conditions

  • Community-acquired Pneumonia

Interventions

DRUG

Beta lactam (amoxicillin / clav. acid OR cefuroxime)

1.2 g 4x/d OR 1.5 g 3x/d IV

DRUG

Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)

1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO

Sponsors & Collaborators

  • University Hospital, Geneva

    collaborator OTHER

  • Swiss National Fund for Scientific Research

    lead OTHER

Principal Investigators

  • Arnaud Perrier, MD · University of Geneva and University Hospital of Geneva

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-01-31
Completion
2013-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818610 on ClinicalTrials.gov